Literature DB >> 25973040

Continuous hemodiafiltration therapy reduces damage of multi-organs by ameliorating of HMGB1/TLR4/NFκB in a dog sepsis model.

Jing Sun1, Shaolan Shi1, Qun Wang1, Kezhou Yu1, Rong Wang1.   

Abstract

In the present study, we investigated whether CVVH can reduce HMGB1, TLR4, NF-κB and other serum cytokine levels, preventing organ injury in a dog sepsis model. A total of 10 dogs were injected with LPS and treated with either CVVH group (n = 5) or nothing (Control, n = 5) for 24 h. EILSA was used for examining the concentration of TNF-α, IL-6, HMGB 1 and TLR4. The histological change of lung, liver and kidney tissues was determined. The mRNA expression of HMGB1, TLR4 and NF-κB was examined by RT-PCR. The protein of HMGB1 and phosphated NF-κB was examined by Western-blot. The levels of serum HMGB1 came to the peak at 8 h, 16 h and then declined. The LPS-induced increase in HMGB1 level was suppressed by CVVH compared with Control. Likewise, serum TNF-α and IL-6 levels decreased with CVVH along with a significant improvement in the function of main organs. Histologic examination revealed significant reduction in inflammation in lung; liver and kidney tissues harvested 24 h after CVVH compared with Control. The mRNA of HMGB1, TLR4 and NF-κB in the kidney was expressed at high level after LPS administration, which was significantly decreased by CVVH. The increased protein expression of HMGB1 and phosphated NF-κB was reduced after CVVH compared with control. CVVH by reducing the level of HMGB1, TLR4, NF-κB and other cytokines could weaken the cascade of cytokines and restore the immune system, and reduce the damage of important organs in sepsis.

Entities:  

Keywords:  CVVH; HMGB1; NF-κB; TLR4; sepsis

Mesh:

Substances:

Year:  2015        PMID: 25973040      PMCID: PMC4396325     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  32 in total

1.  Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine.

Authors:  Stefania Mitola; Mirella Belleri; Chiara Urbinati; Daniela Coltrini; Bianca Sparatore; Marco Pedrazzi; Edon Melloni; Marco Presta
Journal:  J Immunol       Date:  2006-01-01       Impact factor: 5.422

Review 2.  Role of high mobility group box 1 in inflammatory disease: focus on sepsis.

Authors:  Jong-Sup Bae
Journal:  Arch Pharm Res       Date:  2012-10-09       Impact factor: 4.946

3.  Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE).

Authors:  Ding Xu; Jeffrey Young; Danyin Song; Jeffrey D Esko
Journal:  J Biol Chem       Date:  2011-10-11       Impact factor: 5.157

4.  Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization.

Authors:  Frederic Chagnon; Christine N Metz; Richard Bucala; Olivier Lesur
Journal:  Circ Res       Date:  2005-05-05       Impact factor: 17.367

5.  Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis.

Authors:  A Uzawa; M Mori; J Taniguchi; S Masuda; M Muto; S Kuwabara
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection.

Authors:  Hideyuki Yanai; Atsushi Matsuda; Jianbo An; Ryuji Koshiba; Junko Nishio; Hideo Negishi; Hiroaki Ikushima; Takashi Onoe; Hideki Ohdan; Nobuaki Yoshida; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-03       Impact factor: 11.205

7.  The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study.

Authors:  Pål Comstedt; Merete Storgaard; Annmarie T Lassen
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2009-12-27       Impact factor: 2.953

8.  LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro.

Authors:  D Chen; L M Bellussi; D Passali; L Chen
Journal:  Acta Otorhinolaryngol Ital       Date:  2013-12       Impact factor: 2.124

9.  Effect of milrinone on the inflammatory response and NF-kB activation in renal ischemia-reperfusion injury in mice.

Authors:  Hong Soo Jung; Jin-Deok Joo; Dae-Woo Kim; Jang Hyeok In; Misun Roh; Jong-Tae Jeong; Seung June Noh; Jin Woo Choi
Journal:  Korean J Anesthesiol       Date:  2014-02-28

10.  Relationship between vascular reactivity and expression of HMGB1 in a rat model of septic aorta.

Authors:  Satoshi Nishiike; Toshiaki Hiramatsu; Miharu Shiraishi; Yoshimichi Ueda; Hideaki Tsuchida
Journal:  J Anesth       Date:  2013-03-27       Impact factor: 2.078

View more
  7 in total

1.  HMGB1, TGF-β and NF-κB are associated with chronic allograft nephropathy.

Authors:  Shi-Qi Zhao; Zhen-Zhen Xue; Ling-Zhang Wang
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

2.  MicroRNA-142-3p Inhibits Chondrocyte Apoptosis and Inflammation in Osteoarthritis by Targeting HMGB1.

Authors:  Xiuqin Wang; Yanqing Guo; Chunyan Wang; Hong Yu; Xiuxiang Yu; Hongbo Yu
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

3.  miR-340-5p inhibits pancreatic acinar cell inflammation and apoptosis via targeted inhibition of HMGB1.

Authors:  Yazhou Gao; Liming Wang; Zequn Niu; Hui Feng; Jie Liu; Jiangli Sun; Yanxia Gao; Longfei Pan
Journal:  Exp Ther Med       Date:  2021-12-14       Impact factor: 2.447

4.  Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis.

Authors:  Shixiang Zheng; Qinyong Weng; Wenwei Wu; Guohua Ding
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447

Review 5.  The Regulatory Role of High-Mobility Group Protein 1 in Sepsis-Related Immunity.

Authors:  Li Li; Yuan-Qiang Lu
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

6.  Ma Xing Shi Gan Decoction Attenuates PM2.5 Induced Lung Injury via Inhibiting HMGB1/TLR4/NFκB Signal Pathway in Rat.

Authors:  Yu-Xiang Fei; Bo Zhao; Qi-Yang Yin; Yan-Ying Qiu; Guang-Hui Ren; Bo-Wen Wang; Ye-Fang Wang; Wei-Rong Fang; Yun-Man Li
Journal:  Front Pharmacol       Date:  2019-11-14       Impact factor: 5.810

7.  Continuous venovenous hemofiltration decreases mortality and ameliorates acute lung injury in canine model of severe salt water drowning.

Authors:  Jian Chen; Guangming Chen; Daping Xiao; Weihua Peng; Guoqing Yu; Yueyong Lin; Feng Zheng
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-03-31       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.